| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT01333137 Details | 2014-09-04 Interventional | 1 | 11 | Carboplatin Gemcitabine Breast Neoplasm… Triple Negative… Breast Cancer | - - | |||
| NCT01866709 Details | 2014-09-03 Interventional | 4 | 32 | Polystyrene sul… Hyperkalemia | Risk/benefit determination showed study revealed negative safety issues. Due to the high frequency of adverse events in the SPS group, the independent Data Monitoring Committee (iDMC) recommended termination of the study. | |||
| NCT01346930 Details | 2014-09-03 Interventional | 2 | 0 | Macitentan Fibrosis Idiopathic Pulm… Pulmonary Fibro… | Due to Protocol AC-055B201 (MUSIC) not meeting it's primary end point - | |||
| NCT00252967 Details | 2014-09-03 Interventional | 3 | [1 Refs] | 64 | Atorvastatin Atrial Fibrilla… Inflammation | Insufficient power to show therapy difference at interim analysis. Limited enrollment; recurrence rate of AF was slightly higher than other trials indicated that the study sample may be a high-risk population. | ||
| NCT02229760 Details | 2014-09-01 Interventional | 1/2 | 3 | Ritonavir Tipranavir HIV Infections | - - | |||
| NCT00884390 Details | 2014-09-01 Interventional | 4 | 208 | Factor VIII Hemophilia A | See termination reason in detailed description. The study was terminated early by agreement with the EMA before full recruitment was attained, but this is not considered to affect the overall results and the ability of the study to address its objectives. | |||
| NCT01810302 Details | 2014-08-29 Interventional | 2 | 2 | Nicardipine Vasospasm, Intr… Cerebral Vasosp… | Unable to secure drug. This single center study was terminated early due to inability to maintain an adequate drug supply; therefore, statistical analysis of the 2 participants was not done. | |||
| NCT01284205 Details | 2014-08-29 Interventional | 3 | 0 | BCG Vaccine Urinary Bladder… Bladder Cancer | This indication is not being pursued at this point in time. - | |||
| NCT00962936 Details | 2014-08-29 Interventional | 1/2 | 13 | Pidilizumab Hepatitis Hepatitis A Hepatitis C Hepatitis C, Ch… Hepatitis, Chro… Infections Chronic Hepatit… | - - | |||
| NCT00682344 2007-000796-42 Details | 2014-08-28 Interventional | 3 | 7 | Levobupivacaine Surgical Pathol… | - - | |||
| NCT00544778 Details | 2014-08-28 Interventional | 2 | 7 | Dexrazoxane Doxorubicin Ifosfamide Irinotecan Liposomal doxor… Razoxane Osteosarcoma Sarcoma | The study was terminated prematurely due to withdrawal of support by the sponsor. The study was terminated…protocol objectives not met. It was closed prematurely due to withdrawal of support by the sponsor. Subjects have been followed, but there is not enough data generated to continue following the subjects." | |||
| NCT00509366 Details | 2014-08-28 Interventional | 2 | 101 | Cisplatin Docetaxel Gemcitabine Pemetrexed Carcinoma, Non-… Lung Neoplasms Non Small Cell … | Study terminated due to reproducibility issues with genomics prediction model. The microarray-based prediction model of chemotherapy sensitivity, used to allocate patients into the cisplatin treatment arms, was irreproducible and inaccurate. Quality of life measurements were incomplete and could not be analyzed. | |||
| NCT00225173 Details | 2014-08-27 Interventional | 2 | - | Bleomycin Cyclophosphamid… Doxorubicin Etoposide Etoposide phosp… Gemcitabine Prednisone Vinblastine Vincristine Vinorelbine Hodgkin Disease | - - | |||
| NCT02170519 Details | 2014-08-26 Interventional | 4 | 27 | Iloprost Hypertension Hypertension, P… Pulmonary Hyper… | Project was completed - | |||
| NCT01365910 Details | 2014-08-26 Interventional | 2 | 30 | Tyrosine Kinase… Colonic Neoplas… Rectal Neoplasm… Recurrence Recurrent Colon… Recurrent Recta… Stage IVA Colon… Stage IVA Recta… Stage IVB Colon… Stage IVB Recta… | Interim analysis determined the study did not meet criteria to proceed - | |||
| NCT00667277 Details | 2014-08-22 Interventional | 2 | [1 Refs] | 13 | Bevacizumab Primary Myelofi… Myelofibrosis | lack of response activity in the setting of an unacceptable toxicity profile The study was terminated due to lack of response activity in the setting of an unacceptable toxicity profile at the completion of the first stage. | ||
| NCT00683917 Details | 2014-08-21 Interventional | 2 | 10 | Leuprolide Leiomyoma Myofibroma Uterine Fibroid… | Repros stopped the study for safety and FDA put the study on hold for safety. The study was prematurely terminated for safety reasons (Proellex studies were put on clinical hold due to liver toxicity). Sponsor was unable to pay vendor, and was therefore not provided with any study data. | |||
| NCT00385827 2006-001671-38 Details | 2014-08-20 Interventional | 2 | 106 | Mitoxantrone Prednisone Siltuximab Prostatic Neopl… Cancer, Prostat… | Prematurely stopped after Independent Data Monitoring Committee (IDMC) evaluation for lack of
efficacy. Results of few secondary endpoints were not reported as the study was terminated early due to the premature suspension and subsequent halting of study enrollment. | |||
| NCT01442168 Details | 2014-08-19 Interventional | 1/2 | 53 | Atovaquone Malaria Malaria, Falcip… | - - | |||
| NCT00713765 2008-002847-17 Details | 2014-08-15 Interventional | 1 | 33 | Donepezil Alzheimer Disea… Alzheimer's Dis… | Ended prematurely - The trial never commenced. - |